Evidence map›Paper›PMID 39878818›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Disclosing the impact of metformin and methotrexate in adjuvant arthritis in female rats: molecular docking and biochemical insights on visfatin.

Ahmed Mostafa Mahmoud, Esam Mohamed Abu Alfadl, Ahmed R H Ahmed, Azza M A Abouelella, Omar Alshazly, Mamdouh F A Mohamed, Hasan El Allaf, Rasha M Allam

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ahmed Mostafa MahmoudDepartment of Physiology, Faculty of Medicine, Sohag University, Sohag, Egypt.
Esam Mohamed Abu AlfadlDepartment of Rheumatology and Rehabilitation, Faculty of Medicine, Sohag University, Sohag, Egypt.
Ahmed R H AhmedDepartment of Pathology, Faculty of Medicine, Sohag University, Sohag, Egypt.
Azza M A AbouelellaDepartment of Pharmacology, Faculty of Medicine, Sohag University, Sohag, Egypt.
Omar AlshazlyDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag, 82524, Egypt. Omar.alshazly23@gmail.com.
Mamdouh F A MohamedDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag, 82524, Egypt.
Hasan El AllafDepartment of Physiology, Faculty of Medicine, Sohag University, Sohag, Egypt.
Rasha M AllamPharmacology Department, Medical and Clinical Research Institute, National Research Centre, Dokki, Cairo, 12622, Egypt. rasha_senior@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is one of the most common systemic autoimmune inflammatory diseases, with a progressive etiology that results in serious complications and a higher chance of early death. Visfatin, an adipokine, is correlated with disease pathologic features and becomes a key biomarker and therapeutic target for RA. This study aimed to evaluate the anti-arthritic activity of metformin (an antidiabetic drug with anti-inflammatory activities) and methotrexate (the first choice for disease-modifying antirheumatic drugs in RA, with diverse adverse effects) in complete Freund's adjuvant (CFA)-induced arthritis in female rats. Treatment outcomes were assessed using arthritis severity, serum levels of inflammatory markers, and pro-inflammatory adipokine (visfatin). In addition to radiological and histopathological examination, and docking analysis. Results showed that Met, MTX, and Met/MTX significantly (p ≤ 0.05) lowered paw swelling and arthritic score, as well as attenuated serum levels of rheumatoid factor (RF), C-reactive protein (CRP), and visfatin. The combined treatment gives the best results. The previously mentioned findings were further confirmed through radiological and histopathological examinations. In conclusion, the co-administration of metformin could potentiate the anti-arthritic activity of methotrexate, providing a medical strategy for arthritis management.

Indexed as

Antirheumatic AgentsArthritis, ExperimentalMetforminMethotrexateNicotinamide PhosphoribosyltransferaseAnimalsCytokinesDrug Therapy, CombinationFemaleFreund's AdjuvantMolecular Docking SimulationRatsRats, WistarAntirheumatic AgentsCytokinesFreund's AdjuvantMetforminMethotrexateNicotinamide Phosphoribosyltransferasenicotinamide phosphoribosyltransferase, ratMetforminMethotrexateRheumatoid arthritisVisfatin

Identifiers

PMID39878818

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.